Entrectinib -Roche’s Gene-Targeting Drug Shows Promise in Child Brain Tumors


“The young boy was running out of time. His brain tumor was growing so fast that he had trouble putting words together. All standard cancer treatments had failed. Then last summer the child started taking an experimental pill that targeted a rare genetic mutation found inside his tumor. Within months, the malignant growth started to … Continue reading Entrectinib -Roche’s Gene-Targeting Drug Shows Promise in Child Brain Tumors

The ROS1ders Interview Dr. Ross Camidge (16-May-2019)


On May 16, 2019, ROS1der co-founder Janet Freeman-Daily interviewed ROS1 expert D Ross Camidge, MD, PhD, Director of Thoracic Oncology and the Joyce Zeff Chair in Lung Cancer Research at the University of Colorado in a Zoom Webinar. We discussed questions that have arisen among experienced patients in The ROS1ders regarding diagnosis, treatment, and research … Continue reading The ROS1ders Interview Dr. Ross Camidge (16-May-2019)

Presentations on ROS1+ Cancer at IASLC #WCLC2018


Members of The ROS1ders will be attending The International Association for the Study of Lung Cancer’s (IASLC) annual World Conference on Lung Cancer (WCLC) in Toronto, Canada, September 23-26, 2018.  The Twitter hashtag for the conference is #WCLC2018. Presentations that will mention ROS1+ cancer are listed below.  The abstract book containing these and other WCLC … Continue reading Presentations on ROS1+ Cancer at IASLC #WCLC2018

Should we combine TKIs and immunotherapy?


Some researchers think combining immunotherapy and certain targeted therapies called tyrosine kinase inhibitors (TKIs) may be too toxic for patients. This Phase 1/2 study supports that idea. It combined nivolumab and full-dose crizotinib in ALK+ non-small cell lung cancer, and was discontinued for safety reasons when 38% of the first 13 patients developed liver problems … Continue reading Should we combine TKIs and immunotherapy?

#ROS1 Presentations at ESMO 2017


The European Society for Medical Oncology will hold their annual Congress in Madrid, Spain, on September 8-12 this year.  The three presentations that will discuss ROS1 specifically are listed below (you can see the complete abstracts by clicking on the presentation title). 1308PD – Preliminary efficacy and safety of lorlatinib in patients (Pts) with ROS1-positive non-small … Continue reading #ROS1 Presentations at ESMO 2017

TPX-0005 (in trials for ROS1+ cancers) receives orphan drug designation


A TP Therapeutics, Inc. drug designated TPX-0005 received FDA Orphan Drug Designation on June 27, 2017.  The first patient enrolled in March 2017 in the TPX-0005 Phase 1 clinical trial for advanced solid tumors with ROS1, ALK, and NTRK rearrangements. Here is the clinical trial listing on clinicaltrials.gov: NCT03093116:  A Study of TPX-0005 in Patients … Continue reading TPX-0005 (in trials for ROS1+ cancers) receives orphan drug designation